NEW YORK (TheStreet) -- Makers Mark bourbon, Laphroaig Scotch whiskey and Courvoisier cognac are going to have to generate consistent earnings for decades if Suntory's $16 billion takeover of Beam Inc. (BEAM) is going to work out for the Japanese spirits conglomerate.
Suntory's acquisition of Beam, done at a multiple in excess of 20 times Beam's trailing 12-month earnings before interest, taxes, depreciation and amortization (EBITDA), may sound a bit bubbly given that most private equity takeovers come in at a valuation of five-to-eight times EBITDA. The deal's price-to-EBITDA valuation would make Beam among the most expensive stocks on the S&P 500 Index, up there with the likes of Starbucks (SBUX), Amazon (AMZN), Alexion Pharmaceuticals (ALXN), Forest Labs (FRX) and Vertex Pharmaceuticals (VRTX).
5 Best European Stocks To Invest In Right Now: Vanguard Growth Index Fund (VUG)
Vanguard Growth ETF (the Fund), formerly known as Vanguard Growth VIPERs, is an exchange-traded share class of Vanguard Growth Index Fund. The Fund seeks to track the investment performance of the Morgan Stanley Capital International (MSCI) US Prime Market Growth Index (the Index). The Index is designed to represent the large-cap growth segment of the United States equity market.
The Index represents the growth companies of the MSCI US Prime Market 750 Index. The MSCI US Prime Market 750 Index represents the universe of predominantly large-capitalization companies in the United States equity market. The Fund employs a passively managed, full-replication strategy in seeking to track the Index. The Fund invests in all of the Index stocks, holding each stock in approximately the same proportion as its weighting in the Index.
Advisors' Opinion:- [By Mark Salzinger]
Our preferred large-cap growth ETF is Vanguard Growth (VUG), which we feature in all four of our core Best Buys model portfolios. It has fairly broad coverage of growth stocks, with more than 350 holdings. Its expense ratio is a miniscule 0.10%.
- [By Selena Maranjian]
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some growth stocks to your portfolio but don't have the time or expertise to hand-pick a few, the Vanguard Growth ETF (NYSEMKT: VUG ) could save you a lot of trouble. Instead of trying to figure out which companies will perform best, you can use this ETF to invest in lots of them simultaneously.
The basics
ETFs often sport lower expense ratios than their mutual fund cousins. The Vanguard ETF's expense ratio -- its annual fee -- is a very low 0.10%.
This ETF aspires to beat the S&P 500 soundly, but over the past three and five years, it has slightly underperformed and outperformed it, respectively. As with most investments, of course, we can't expect outstanding performances in every quarter or year. Investors with conviction need to wait for their holdings to deliver.
Top 10 Japanese Stocks To Buy Right Now: CombiMatrix Corporation(CBMX)
CombiMatrix Corporation, a molecular diagnostics company, operates primarily in the fields of genetic analysis and molecular diagnostics in the United States. The company, through its wholly owned subsidiary, CombiMatrix Diagnostics, operates a diagnostics reference laboratory that provides DNA-based clinical diagnostic testing services to physicians, hospitals, and other laboratories in two primary areas, including prenatal and postnatal developmental disorders, and oncology. It offers a suite of developmental disorder array tests on the prenatal and postnatal application of array-comparative genomic hybridization in diagnosing genomic syndromes associated with developmental delays, autism spectrum disorders, dysmorphic features, and/or birth defects. The company also provides DNAarray?Heme Profile test to address various common hematological malignancies, including chronic lymphocytic leukemia; DNAarray?HER2 PRO test for breast cancer; and DNAarray?Tumor Profile test for the analysis of solid tumors, including breast, colon, lung, prostate, and brain tumors. In addition, it focuses on developing a series of drug compounds to address various oncology-related diseases. CombiMatrix Corporation was founded in 1995 and is based in Irvine, California.
Advisors' Opinion:- [By Bryan Murphy]
Looking for a couple of long (bullish) trading ideas on a day when the market is dragging pretty much everything lower? There are two names that fit the bill...CombiMatrix Corp. (NASDAQ:CBMX) and Banro Corporation (NYSEMKT:BAA). CBMX is an "almost" small cap stock that deserves a place on your watchlist while we wait for it to do one more thing. Meanwhile, BAA is something worth going ahead and taking a swing on now, not despite the market's tumble, but because of it.
- [By Wallace Witkowski]
Also, shares of Combimatrix Corp. (CBMX) rose 7.5% to $2.73 in moderate volume late Friday following a Securities and Exchange Commission filing showing Longwood Capital Partners acquired a 5.1% stake in the microcap molecular diagnostics company.
Top 10 Japanese Stocks To Buy Right Now: iShares iBoxx $ Investment Grade Corporate Bond ETF (LQD)
iShares iBoxx $ InvesTop Investment Grade Corporate Bond Fund, formerly known as iShares GS $ InvesTop Corporate Bond Fund, seeks investment results that correspond generally to the price and yield performance of the corporate bond market as defined by the iBoxx $ Liquid Investment Grade Index (formerly the GS $ InvesTop Index) (the Index). The Fund invests in a representative sample of the securities in the Index, which has a similar investment profile as the Index.
The Index measures the performance of a fixed number of highly liquid investment-grade corporate bonds. The Index is a rules-based index consisting of up to 100 highly liquid, investment-grade, United States dollar-denominated corporate bonds that seek to maximize liquidity while maintaining representation of the corporate bond market. The Fund's investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion:- [By Eric Mancini]
A good example of this low duration advantage is 2013. The U.S. investment grade bond index, with the I-Shares Iboxx ETF (NYSE: LQD) as a reference, was down 2.2 percent on a total return basis, while the Chinese renminbi-denominated investment grade index, using the Power Shares Chinese Dim Sum ETF (NYSE: DSUM) as the proxy, was up 6.3 percent!
Top 10 Japanese Stocks To Buy Right Now: Novo Nordisk A/S (NVO)
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes care segment covers insulins, oral antidiabetic drugs, and other protein-related products and projects comprising glucagon and protein-related delivery systems, as well as GLP-1 analogue. The Biopharmaceuticals segment provides products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation therapy. Its products are marketed and distributed through subsidiaries, distributors, and independent agents in 180 countries. Novo Nordisk A/S has a collaboration agreement with Archimedes, Inc. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Advisors' Opinion:- [By Max Macaluso, Ph.D.]
Last week, pharmaceutical giant Eli Lilly (NYSE: LLY ) announced that its cancer drug candidate enzastaurin failed its late-stage clinical trial. Despite this news, shares remained practically flat following the announcement. Was this drug central to Lilly's pipeline, or was it one of many oncology drugs that the company is testing? Should investors instead be worried about Lilly's upcoming patent expirations? What about the ever-present competition from diabetes powerhouse��Novo Nordisk (NYSE: NVO ) ? Health-care analyst Max Macaluso discusses these topics in the following video.
- [By Rich Duprey]
What started with the Food Network not renewing her TV show contract has now turned into a complete rout, with major corporations including Wal-Mart (NYSE: WMT ) , Target, Home Depot, and Novo Nordisk (NYSE: NVO ) all dropping their association with her.
Top 10 Japanese Stocks To Buy Right Now: Safety Insurance Group Inc.(SAFT)
Safety Insurance Group, Inc., through its subsidiaries, provides private passenger automobile insurance products primarily in Massachusetts and New Hampshire. The company?s private passenger automobile policies offer coverage for bodily injury and property damage to others, no-fault personal injury coverage for the insured/insured?s car occupants, and physical damage coverage for an insured?s own vehicle for collision or other perils. It also provides commercial automobile policies that offer insurance for commercial vehicles used for business purposes, including private passenger-type vehicles, trucks, tractors and trailers, insure individual vehicles, and commercial fleets; and homeowners policies, which provide coverage for losses to a dwelling and its contents from various perils, and coverage for liability to others arising from ownership or occupancy. It writes policies on homes, condominiums, and apartments. In addition, the company offers business owners policie s that cover apartments and residential condominiums, limited cooking restaurants, office condominiums, processing and services businesses, special trade contractors, and wholesaling businesses. Further, it provides commercial package policies, which offer property, general liability, crime, and inland marine insurance for business enterprises; personal umbrella policies that provide personal excess liability coverage over and above the limits of individual automobile, watercraft, and homeowner?s insurance policies; and commercial umbrella policies to clients for whom the company underwrites commercial automobile and business owner policies. Additionally, the company underwrites dwelling fire insurance, inland marine coverage, and watercraft coverage. Safety Insurance Group, Inc. was founded in 1979 and is headquartered in Boston, Massachusetts.
Advisors' Opinion:- [By John Udovich]
Auto sales are booming and that�� good news for large cap auto insurer�the Progressive Corporation (NYSE: PGR) along with small cap auto insurers Safety Insurance Group, Inc (NASDAQ: SAFT) and�Mercury General Corporation (NYSE: MCY) as they offer income to yield hungry investors as well as income in the form of dividends. Specifically, a Yahoo! Autos blog recently noted that last month, automakers sold 1.5 million new vehicles for the highest rate in years with�most industry forecasters expecting sales to�return to the level they hit before the 2008 recession of 16 million vehicles a year. The blog post then went on to note the three forces driving auto sales:
- [By Selena Maranjian]
Safety Insurance (NASDAQ: SAFT ) , also impressive among high dividend stocks, is a rather boring company that's good at what it does�-- offering auto insurance, primarily in New England. Recently yielding 4.7%, its dividend has grown by 8.5% annually over the past five years and 24% annually over the past decade. (Its last hike, last year, was 20%.) Its payout ratio is 67%, which is not too worrisome. Its forward P/E ratio of 11 compares favorably with the five-year average near 18, and its PEG ratio is an appealing 0.70, as well.
Top 10 Japanese Stocks To Buy Right Now: Sociedad Quimica y Minera S.A.(SQM)
Chemical and Mining Company of Chile Inc. engages in the production and sale of fertilizers and specialty chemicals in Chile and internationally. The company?s specialty plant nutrients include potassium nitrate, sodium nitrate, sodium potassium nitrate, and specialty blends for crops, such as vegetables, fruits, flowers, potatoes, and cotton, as well as Ultrasol for application via fertigation; Qrop for field application; Speedfol for foliar application; Allganic for organic farming; and Nutrilake for aquaculture. It also produces iodine and iodine derivatives, which are used in a range of medical, pharmaceutical, agricultural, and industrial applications, including X-ray contrast media, polarizing films for liquid crystal displays (LCDs), antiseptics, biocides, and disinfectants; and in the synthesis of pharmaceuticals, herbicides, electronics, pigments, dye components, and heat stabilizers. In addition, the company provides lithium carbonate for use in various applicat ions comprising batteries, frits for the ceramic and enamel industries, heat-resistant glass, primary aluminum, lithium bromine for use in air conditioner equipment, and continuous casting powder for steel extrusion, pharmaceuticals, and lithium derivatives; and lithium hydroxide, which is used as a raw material in the lubricating grease industry. Further, it offers various industrial chemicals, such as sodium nitrate, potassium nitrate, and boric acid; and potassium chloride and potassium sulfate. The company was founded in 1968 and is based in Santiago, Chile.
Advisors' Opinion:- [By Carlton Delfeld]
Chemical and Mining Company of Chile (SQM) has long been a darling of global investors looking for plays for more productive farmland. However, the stock has plunged 59% in 2013, due to weak fertilizer and phosphate prices.
- [By Chris Damas]
Other players, such as K+S (KPLUY.PK), Israel Chemicals and APC, Belaruskali and Soquimich (SQM) maintained their world shares at Uralkali's expense.
- [By Dan Newman]
Resilient resources
While weakness in fertilizer markets hurt Sociedad Quimica y Minera (NYSE: SQM ) this year, higher sales volume and margins in other businesses helped the company grow earnings 19% over 2012. Sociedad has a hand in many industrial resources, from iodine to lithium, and it boasts healthy double-digit profit margins. It is also expanding its production capacity to keep up with a world hungry for more fertilizer-based food and lithium-based batteries. Still, the company failed to meet recent expectations and has missed the market rally this year. If markets get spooked and head downward, investors could find peace of mind in the intrinsic value of Sociedad's physical resources, as well as its 2.6% dividend yield.
Top 10 Japanese Stocks To Buy Right Now: Onconova Therapeutics Inc (ONTX)
Onconova Therapeutics, Inc. (Onconova), incorporated on December 22, 1998, is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways, which promote cancer. It has three clinical-stage product candidates and six preclinical programs. Its preclinical pipeline includes six programs, which target kinases, cellular metabolism or division.
Rigosertib
Rigosertib, the Company�� product candidate, is being tested in a range of ongoing Phase-II and Phase-III clinical trials. The Company is conducting a pivotal phase-III trial of rigosertib under a Special Protocol Assessment (SPA), from the United States Food and Drug Administration (FDA), for higher risk myelodysplastic syndromes (MDS). The Company is also evaluating rigosertib in a Phase-III trial for metastatic pancreatic cancer, in two Phase-II trials for transfusion-dependent lower risk MDS, and in a Phase-II trial for head and neck cancers. Rigosertib has been granted orphan drug status for MDS in both the United States and Europe, as well as orphan drug status for pancreatic cancer in the United States. Baxter Healthcare SA (Baxter), a subsidiary of Baxter International Inc., has commercialization rights for rigosertib in Europe and SymBio Pharmaceuticals Limited (SymBio), has commercialization rights in Japan and Korea. Rigosertib is an inhibitor of two cellular signaling pathways: phosphoinositide 3-kinase (PI3K), and polo-like kinase (PLK), both of which are frequently over-active in cancer cells. By inhibiting the PI3K pathway in cancer cells, rigosertib promotes tumor cell apoptosis, or programmed cell death. It is testing both intravenous and oral formulations of rigosertib, referred to as rigosertib IV and rigosertib Oral, in clinical trials.
ON 013105
The Company�� clinical-stage product candidate, ON 013105, is i! n a Phase I trial in patients with relapsed or refractory lymphoma, including an aggressive form of non-Hodgkin's lymphoma identified as mantle cell lymphoma (MCL), and acute lymphoid leukemia (ALL). ON 013105 suppresses the accumulation of cyclin D1 in cancer cells.
Recilisib
The Company�� clinical-stage product candidate, recilisib, is being developed in collaboration with the United States Department of Defense (DoD), for acute radiation syndromes (ARS). The Company has completed four Phase-I trials to evaluate the safety and pharmacokinetics of recilisib in healthy human adult subjects using both subcutaneous and oral formulations, referred to as recilisib SC and recilisib Oral.
Preclinical Programs
The Company�� ON 1231320 is a specific inhibitor of Polo-like Kinase 2 (PLK2), and in preclinical studies, it induced mitotic arrest and reduced tumor burden in mice injected subcutaneously with colon tumor and triple-negative breast cancer cells. The Company�� ON 123300 inhibits the activity of two kinases, cyclin-dependent kinase 4 (CDK4), and AMP-activated protein kinase 5 (ARK5). Its ON 108600 is a dual inhibitor of two growth-regulatory kinases. Cyclin-dependent kinase 9 is over expressed in several cancers, including leukemias and lymphomas. Casein kinase 2 is overexpressed in a range of tumor types. ON 044580 inhibits mutant forms of the two target kinases, including Janus Kinase 2 (JAK2) and imatinib-resistant Bcr-Abl Kinase (Bcr-Abl). Its ON 24 compounds cause tubulin to depolymerize, inducing mitotic arrest in cultured tumor cell lines. Its ON 146040 inhibits the growth of a range of blood cancer cell lines, including Burkitt's lymphoma, MCL, multiple myeloma and chronic myeloid leukemia.
The Company competes with Eisai Inc., Celgene Corporation, Genentech, Inc., Cell Therapeutics, Inc., Cyclacel Pharmaceuticals, Inc., Telik, Inc., Spectrum Pharmaceuticals, Inc., Astex, Array BioPharma Inc., Astellas Pharma, Inc., Threshold! Pharmace! uticals, Inc., Pharmacyclics Inc., Soligenix, Inc., Cellerant Therapeutics, Inc. and Cleveland BioLabs, Inc.
Advisors' Opinion:- [By Roberto Pedone]
One under-$10 clinical-state biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Onconova Therapeutics (ONTX), which focuses on discovering and developing small molecule drug candidates to treat cancer. This stock has been destroyed by the short-sellers so far in 2014, with shares off sharply by 56%.
If you glance at the chart for Onconova Therapeutics, you'll notice that this stock has been trending sideways and consolidating right below its 50-day moving average for the last few weeks. This consolidation pattern is occurring right after shares of ONTX recently spiked sharply higher from its low of $4.10 to its high of $5.52 a share. Shares of ONTX are now trending within range of breaking out of that consolidation pattern and potentially heading higher.
Traders should now look for long-biased trades in ONTX if it manages to break out above its 50-day moving average of $5.09 a share and then once it takes out some more key overhead resistance levels at $5.24 to $5.52 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 203,756 shares. If that breakout triggers soon, then ONTX will set up to re-test or possibly take out its next major overhead resistance levels at $6.27 to $7 a share.
Traders can look to buy ONTX off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $4.75 to right around $4.50 a share. One can also buy ONTX off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By gurujx]
Onconova Therapeutics Inc (ONTX) Reached the 3-year Low of $4.18
The prices of Onconova Therapeutics Inc (ONTX) shares have declined to close to the 3-year low of $4.18, which is 86.8% off the 3-year high of $31.13.
- [By Roberto Pedone]
Onconova Therapeutics (ONTX), a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. This stock closed up 2.5% to $5.15 in Thursday's trading session.
Thursday's Range: $4.97-$5.19
52-Week Range: $4.10-$31.13
Thursday's Volume: 132,000
Three-Month Average Volume: 216,102From a technical perspective, ONTX trended modestly higher here with lighter-than-average volume. This stock has been uptrending over the last few weeks, with shares moving higher from its low of $4.10 to its recent high of $5.52. During that uptrend, shares of ONTX have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of ONTX within range of triggering a near-term breakout trade. That trade will hit if ONTX manages to take out Thursday's intraday high of $5.19 to some more key overhead resistance at $5.52 with high volume.
Traders should now look for long-biased trades in ONTX as long as it's trending above some near-term support levels at $4.80 or at $4.50 and then once it sustains a move or close above those breakout levels with volume that hits near or above 216,102 shares. If that breakout gets underway soon, then ONTX will set up to re-test or possibly take out its next major overhead resistance levels at $5.83 to $6.27. Any high-volume move above those levels will then give ONTX a chance to tag $7.
No comments:
Post a Comment